FDA grants fast track designation to IV cannabidiol for neonatal hypoxic/ischemic encephalopathy


GW Pharmaceuticals recently announced that the FDA has granted fast track designation to an intravenous form of cannabidiol for the treatment of neonatal hypoxic/ischemic encephalopathy.Additionally, the European Medicines Agency has granted orphan designation for the same product to treat perinatal asphyxia, for which the manufacturer has already received orphan drug designation from the FDA.

Source: FDA grants fast track designation to IV cannabidiol for neonatal hypoxic/ischemic encephalopathy

Leave a comment

Your email address will not be published. Required fields are marked *